QIAGEN Expands Supervisory Board With Appointment of a New Member

Rhea-AI Summary

QIAGEN has appointed Thomas Ebeling to its Supervisory Board, effective immediately. Ebeling, with a robust background in healthcare and management, previously served as CEO of ProSiebenSat.1 Media and held significant roles at Novartis. This addition expands the Board to eight members, enhancing its expertise in Life Sciences and diagnostics. Lawrence Rosen, Chairman of the Supervisory Board, emphasized the commitment to corporate governance and value creation for stakeholders.

Positive

• Thomas Ebeling's extensive experience in healthcare could provide valuable insights to the board.
• The appointment reflects a continued commitment to enhancing governance and expertise in the life sciences sector.

Negative

• Ebeling's prior role in media may raise questions about his direct experience in diagnostics compared to other members.
• Potential concerns regarding continuity as a new member joins the board amid ongoing reviews and changes.

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the appointment of Thomas Ebeling, a leading international executive with extensive experience in the healthcare, media and consumer goods industries, as a member of the Supervisory Board with immediate effect.

Mr. Ebeling joins QIAGEN as part of a process launched by the Supervisory Board in 2020 to further complement and enhance the Board’s already extensive experience in Life Sciences and diagnostics. The addition of Mr. Ebeling brings the number of current Supervisory Board members to eight.

“On behalf of the Supervisory Board and Managing Board, I would like to welcome Thomas Ebeling to QIAGEN. This appointment further deepens our expertise and experience in many ways, in particular given his international background in healthcare and extensive experience in general management,” said Lawrence Rosen, Chairman of the Supervisory Board. “As we continue the review process initiated in 2020, the Supervisory Board continues to pursue the highest level of excellence in corporate governance and support of the management team to create value for QIAGEN’s stakeholders, including its shareholders.”

Mr. Ebeling has been an advisor in recent years to various businesses after having served as the CEO of the publicly-listed German media group ProSiebenSat.1 Media from 2009 to 2018. Prior to that, he worked for the global healthcare company Novartis from 1997 to 2008, including roles as CEO of Novartis Pharmaceuticals and also as CEO of Novartis Consumer Health. He began his career in 1987 and held various positions in marketing and sales in the consumer goods industry before joining Novartis. Mr. Ebeling, who has a degree in psychology from the University of Hamburg, has previously served on the Supervisory Boards of Bayer AG and Lonza AG.

Please find the full press release here.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005852/en/

FAQ

Who is Thomas Ebeling and what is his background?

Thomas Ebeling is a seasoned executive with experience in healthcare, having previously served as CEO at ProSiebenSat.1 Media and held key roles at Novartis.

What is the significance of Thomas Ebeling's appointment to QIAGEN's Supervisory Board?

Ebeling's appointment aims to enhance the board's expertise in life sciences and diagnostics, reflecting QIAGEN's commitment to strong corporate governance.

How many members are currently on QIAGEN's Supervisory Board?

With Thomas Ebeling's appointment, QIAGEN's Supervisory Board now comprises eight members.

What impact might Thomas Ebeling's appointment have on QIAGEN shareholders?

Ebeling's healthcare experience could lead to better strategic decisions, potentially increasing shareholder value.

When did the process for enhancing the Supervisory Board at QIAGEN begin?

The process to enhance the Supervisory Board was launched in 2020.